%20--%3e%3csvg%20xmlns:dc='http://purl.org/dc/elements/1.1/'%20xmlns:cc='http://creativecommons.org/ns%23'%20xmlns:rdf='http://www.w3.org/1999/02/22-rdf-syntax-ns%23'%20xmlns:svg='http://www.w3.org/2000/svg'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20width='640'%20height='640'%20viewBox='0%200%20169.33333%20169.33333'%20version='1.1'%20id='svg8'%20inkscape:version='0.92.2%20(5c3e80d,%202017-08-06)'%20sodipodi:docname='nen_logo_white.svg'%3e%3cdefs%20id='defs2'%20/%3e%3csodipodi:namedview%20id='base'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageopacity='0.0'%20inkscape:pageshadow='2'%20inkscape:zoom='0.98994949'%20inkscape:cx='-236.72488'%20inkscape:cy='268.83927'%20inkscape:document-units='px'%20inkscape:current-layer='layer1'%20showgrid='false'%20inkscape:window-width='1768'%20inkscape:window-height='1177'%20inkscape:window-x='-8'%20inkscape:window-y='-8'%20inkscape:window-maximized='1'%20units='px'%20/%3e%3cmetadata%20id='metadata5'%3e%3crdf:RDF%3e%3ccc:Work%20rdf:about=''%3e%3cdc:format%3eimage/svg+xml%3c/dc:format%3e%3cdc:type%20rdf:resource='http://purl.org/dc/dcmitype/StillImage'%20/%3e%3cdc:title%20/%3e%3c/cc:Work%3e%3c/rdf:RDF%3e%3c/metadata%3e%3cg%20inkscape:label='Vrstva%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(0,-127.66666)'%3e%3cpath%20style='fill:%23ffffff;fill-opacity:1;stroke-width:0.26439872'%20d='m%2077.556333,296.94592%20c%20-16.776995,-1.71441%20-31.092961,-7.21288%20-43.88808,-16.85655%20-5.505068,-4.14916%20-11.341079,-9.84555%20-15.367542,-14.99987%20-3.715123,-4.75577%20-3.536062,-4.36131%20-3.536062,-7.78966%200,-20.8928%206.658718,-42.83523%2018.329812,-60.40214%204.496853,-6.7685%2011.072874,-14.27674%2015.511604,-17.71051%201.328723,-1.02789%201.339214,-1.04618%20-1.26318,2.20258%20-7.618886,9.51124%20-11.186416,19.40971%20-11.21176,31.1082%20-0.01716,7.92594%201.333566,14.18886%204.533577,21.0207%205.70149,12.17238%2016.321365,21.58054%2029.1187,25.79631%205.640453,1.8581%208.226303,2.23298%2015.30794,2.21925%20l%206.213074,-0.0121%205.552107,-1.14186%20c%2011.107587,-2.28443%2018.911177,-5.0227%2026.967377,-9.46281%2011.34618,-6.25339%2021.69634,-15.40328%2029.25225,-25.86%205.68532,-7.86799%2010.65464,-18.18328%2013.21997,-27.44195%200.45189,-1.63095%200.86609,-3.01493%200.92045,-3.07553%200.35987,-0.40116%200.91882,1.95479%201.59443,6.72046%200.75234,5.30691%200.67873,17.87633%20-0.13548,23.13599%20-2.42868,15.68892%20-8.33836,29.19829%20-18.10184,41.38038%20-2.72086,3.39488%20-9.07839,9.75301%20-12.47294,12.47413%20-12.14462,9.73532%20-25.77675,15.70978%20-41.244217,18.07581%20-2.950038,0.45126%20-5.177306,0.58254%20-10.972023,0.64669%20-3.998837,0.0443%20-7.746511,0.0319%20-8.328167,-0.0276%20z%20M%20113.38065,252.3071%20c%200,-0.0643%201.10569,-1.00638%202.4571,-2.09343%208.55108,-6.87832%2014.3692,-15.9125%2016.84432,-26.15525%205.03964,-20.85545%20-4.12487,-42.34946%20-22.85355,-53.59957%20-9.66108,-5.80332%20-22.011771,-8.00628%20-33.461919,-5.96856%20-15.106895,2.68851%20-29.421473,9.43717%20-41.376418,19.50707%20-3.263298,2.74876%20-9.346745,9.01681%20-12.007135,12.37152%20-9.395698,11.84781%20-15.536592,25.80989%20-18.002543,40.93098%20-0.1977934,1.21285%20-0.4264418,1.89308%20-0.6151859,1.83016%20C%203.5316141,238.85209%201.0352778,227.76819%200.33483243,221.23438%20-0.20889386,216.16247%20-0.070674,205.85978%200.60634784,200.99608%203.7988747,178.06107%2015.815223,157.83259%2034.461411,144.00403%20c%2011.072988,-8.21205%2024.657607,-13.70638%2038.926158,-15.74378%203.971462,-0.56708%2014.914188,-0.79182%2018.944071,-0.38908%2020.7314,2.07191%2039.07733,10.85429%2053.2022,25.46844%204.7635,4.92852%208.46678,9.69574%2011.68212,15.03837%201.30575,2.16965%201.37471,2.3764%201.37471,4.12201%200,5.05952%20-1.44548,15.34698%20-3.07515,21.8858%20-4.56382,18.31176%20-12.95518,33.46309%20-25.12773,45.37034%20-5.04281,4.9329%20-9.1727,8.1769%20-14.3914,11.30436%20-2.16625,1.29819%20-2.61574,1.51241%20-2.61574,1.24661%20z'%20id='path16'%20inkscape:connector-curvature='0'%20/%3e%3cpath%20style='fill:%23000000;stroke-width:0.26458332'%20d=''%20id='path10'%20inkscape:connector-curvature='0'%20/%3e%3cpath%20style='fill:%23000000;stroke-width:0.26458332'%20d=''%20id='path8'%20inkscape:connector-curvature='0'%20/%3e%3c/g%3e%3c/svg%3e)
Biologická léčba 2026 II
Části
| Zobrazit detail | ||||
|---|---|---|---|---|
| N006/26/V00018136/001 | I. Everolimus (ATC L01EG02) | Antineoplastika | Neukončen | |
| N006/26/V00018136/002 | II. Axitinib (ATC L01EK01) | Antineoplastika | Neukončen | |
| N006/26/V00018136/003 | III. Denosumab (ATC M05BX04) | Antineoplastika | Neukončen |